Loading...
•
Dec 31, 2024
OrthoPediatrics Q4 2024 Earnings Report
OrthoPediatrics reported strong revenue growth but widened net losses in Q4 2024.
Key Takeaways
OrthoPediatrics Corp. reported Q4 2024 revenue of $52.7 million, up 40% year-over-year, driven by strong growth in Trauma and Deformity, Scoliosis, and the addition of Boston O&P. Despite this, the company reported a net loss of $16.1 million, widening from $6.7 million in the prior year. Adjusted EBITDA improved to $3.0 million from $1.3 million. Gross margin declined slightly due to reclassified costs. The company reiterated its 2025 revenue guidance of $235 million to $242 million.
Q4 2024 revenue increased 40% year-over-year to $52.7 million.
Net loss widened to $16.1 million, or $0.69 per share.
Adjusted EPS was -$0.29, reflecting restructuring and impairment charges.
Adjusted EBITDA improved to $3.0 million, up from $1.3 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
OrthoPediatrics anticipates continued revenue growth in 2025, targeting $235 million to $242 million in revenue, with improvements in adjusted EBITDA and cash flow.
Positive Outlook
- 2025 revenue guidance of $235M to $242M, representing 15-18% growth.
- Expected adjusted EBITDA between $15M and $17M in 2025.
- Improved free cash flow expected in Q4 2025.
- Expansion in Trauma, Deformity, and Scoliosis expected to drive growth.
- Further integration of Boston O&P acquisition anticipated to enhance financials.
Challenges Ahead
- Continued net losses expected in the near term.
- Restructuring costs from facility closures may impact profitability.
- Potential margin pressure from increased operating expenses.
- International growth remains slower than domestic expansion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...